Report: Small European biotechs suffer from lack of funds

04/14/2005 | Wall Street Journal, The

A report from Critical I found the European biotech industry is being held back by a financial structure unable to help firms move treatments into late-stage research. Because smaller biotechs are unable to secure sufficient funding, many companies close after three to four years. An official with EuropaBio says, "it is crucial the European Union reconsiders how it should stimulate the market to invest in innovation."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD